Annals of Surgical Oncology

, Volume 15, Issue 5, pp 1544–1546 | Cite as

Local Control, Aggressive Surgery, and Overall Survival for Breast Cancer

Breast Oncology
  • 39 Downloads

References

  1. 1.
    Morrogh M, Borgen PI, King TA. The importance of local control in early-stage breast cancer: a historical review and a discussion of ongoing issues. Ann Surg Oncol (in press)Google Scholar
  2. 2.
    Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 366: 2087–106.Google Scholar
  3. 3.
    Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003;10:718–21PubMedCrossRefGoogle Scholar
  4. 4.
    Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005;5:737–45PubMedCrossRefGoogle Scholar
  5. 5.
    Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 2007;25:5203–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Lostumbo L, Carbine N, Wallace J, et al. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2004(4):CD002748Google Scholar
  7. 7.
    Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of hereditary breast ovarian cancer. Ann Surg Oncol 2007; doi: 10.1245/s10434-007-9612-4 (in press)
  8. 8.
    NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA 1991;265:391–5CrossRefGoogle Scholar
  9. 9.
    Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308–12PubMedCrossRefGoogle Scholar
  10. 10.
    Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007;4:578–90PubMedCrossRefGoogle Scholar
  11. 11.
    Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:1555–6PubMedCrossRefGoogle Scholar
  12. 12.
    Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006;24:2437–43PubMedCrossRefGoogle Scholar
  13. 13.
    Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002;9:607–9PubMedGoogle Scholar
  14. 14.
    Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002;9:941–3PubMedGoogle Scholar
  15. 15.
    Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rationale of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030–4PubMedCrossRefGoogle Scholar
  16. 16.
    Chung DC, Yoon SS, Lauwers GY, et al. Case records of the Massachusetts General Hospital. Case. 22–2007A woman with a family history of gastric and breast cancer. Nat Clin Pract Oncol 2007;357:283–91Google Scholar
  17. 17.
    Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007;245:873–9PubMedCrossRefGoogle Scholar
  18. 18.
    Roukos DH, Lorenz M, Karakostas K, et al. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001;84:1602–9PubMedCrossRefGoogle Scholar
  19. 19.
    Roukos DH. Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 1999;6:46–56PubMedCrossRefGoogle Scholar
  20. 20.
    Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 2000;7:253–5PubMedCrossRefGoogle Scholar
  21. 21.
    Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 2004;11:127–9PubMedCrossRefGoogle Scholar
  22. 22.
    Roukos DH, Hottenrott C, Encke A, et al. Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 1994;3:115–25PubMedCrossRefGoogle Scholar
  23. 23.
    Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005;2:98–107PubMedCrossRefGoogle Scholar
  24. 24.
    Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004;11:727–30PubMedCrossRefGoogle Scholar
  25. 25.
    Roukos DH, Hottenrott C, Lorenz M, et al. A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach. An analysis of early results and long-term survival. J Cancer Res Clin Oncol 1990;116:307–11PubMedCrossRefGoogle Scholar
  26. 26.
    Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002;81:59–62PubMedCrossRefGoogle Scholar
  27. 27.
    Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 1998;80:16–24PubMedGoogle Scholar
  28. 28.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. Nat Clin Pract Oncol 2001;345:725–30Google Scholar
  29. 29.
    Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002;9:220–1PubMedCrossRefGoogle Scholar
  30. 30.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. Nat Clin Pract Oncol 2006;355:11–20Google Scholar
  31. 31.
    Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007;14:2691–5PubMedGoogle Scholar
  32. 32.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–30PubMedCrossRefGoogle Scholar
  33. 33.
    Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931–9PubMedCrossRefGoogle Scholar
  34. 34.
    Liakakos T, Roukos DH. More controversy than ever – Challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol (in press)Google Scholar
  35. 35.
    Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (in press)Google Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  1. 1.3rd Department of SurgeryAthens UniversityAthensGreece
  2. 2.Department of Plastic Surgery and BurnsIoannina University School of MedicineIoanninaGreece

Personalised recommendations